Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Pfizer said it will present late-breaking Phase 3 survival results for sigvotatug vedotin in previously treated non-squamous NSCLC on Oct. 25, 2026, alongside other oncology data at ESMO 2026 in Madrid.
Pfizer said it will present data from 45 company-sponsored, investigator-sponsored and collaborative research abstracts at the European Society for Medical Oncology congress in Madrid, Spain, on Oct. 23-27, 2026.
Pfizer Inc. (NYSE:PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026 in Madrid, Spain. The presentations include 11 oral presentations spanning…